As 2024 comes to a close, we would like to celebrate the advancements made in small cell lung cancer (#SCLC) that provide hope. This tremendous progress by clinical trials reflects the innumerable sacrifices made by such dedicated patients & their wonderful families. Thank you!

Join us on 11/25 for a Facebook Live w/ Dr. Trudy Oliver (@DukeMedSchool) to discuss the origins of #smallcell #lungcancer and its impact on plasticity. Moderated by @drshieldsmd (@IUHealth @SCLCSMASHERS) Ann Fish-Steagall (@lungevity). Tune in by visiting https://t.co/UMN7nNl2O9

Our 2nd #keynote speaker, Dr. Greg Kalemkerian from University of Michigan delivers an overview of the current and historic landscape of the treatment of #SCLC @SclcSMASHERS #LCSM #Oncology

Thank you @ConquerCancerFd for highlighting how important it is to change the stigma, nihilism, and culture surrounding a diagnosis of lung cancer. Anyone with lungs 🫁 can be diagnosed with lung cancer, and no one deserves lung cancer. Patients with #SCLC deserve MORE

Unfortunately, while DLL3 is widely expressed (93%+) in tumors post-SCLC transformation ( https://t.co/ySAC2zeX7g), it is not clearly an actionable or biologically relevant target for transformed SCLC. This is similar to EGFR alterations and anti-PD-1/PD-L1 therapies, despite high

A true giant in the field of small cell lung cancer! An absolute honor to have Dr. Anish Thomas (@NIH) as a visiting professor at @IUCancerCenter, presenting his groundbreaking research with a “reverse translational” approach (patient bedside to the bench, and back!) on #SCLC.

This morning’s DeLLphi presentation @myESMO brings so much hope to our #lungcancer community. Love seeing fresh hope for those with small cell lung cancer. #ESMO25

Tarlatamab incorporated upfront with chemo-immunotherapy breaks all the known stats in first-line SCLC. No new data safety concerns. Awaiting data from randomized ph3 trial, but likely to be the next SoC. #ESMO25 #SCLC @SclcSMASHERS

🔥Off the press: #IDeate-Lung01 IDxD Ifinatamab Deruxtecan (B7 H3 ADC) in Patients With Extensive-Stage SCLC: ▶️ Phase 2 N=183 ORR 48.2%, mPFS 4.9 mos ▶️Any TRAEs 89%, ILD 12% ▶️ Phase3 ongoing @SclcSMASHERS | Journal of Clinical Oncology

A lifelong dream came true today. Almost exactly 25 years ago today, I lost my strong Marine father to small cell lung cancer. Lost and broken into a million pieces, I sought out Dr. John Minna as a teenager to learn how I could become a translational thoracic oncologist to

Thank you to Dr. Alder @LauraAlderMD, Dr. Clark, Dr. Dave, Dr. Crawford, and the wonderful faculty and staff from @DukeCancer for such a warm welcome. An incredibly thoughtful, invigorating, and clinically meaningful conference 🧬🥼on bispecifics and novel agents in oncology,

Dr. Toby Campbell (@UWCarbone) will join @drshieldsmd (@TheShieldsLab) and LUNGevity's @nursesteagall to discuss #palliativecare and answer your questions during an interactive Facebook Live. Tune in on 10/14 by visiting https://t.co/H8jXESKsJ1 @sclcsmashers #lcsm

Report @JTOonline on DLL3 expression in #EGFR NSCLC after #SCLC transformation. DLL3 positive in 11/12 patients. Two of these patients received tarlatamab (one with osimertinib) with clinical benefit. Need prospective data here! https://t.co/FmnOO32AYR

Dr. @drshieldsmd at #DCLung25 highlights some of the updates for initial therapy in #SCLC. Consolidation durvalumab for limited stage SCLC now standard. For extensive stage SCLC, after initial chemo-immunotherapy, maintenance atezolizumab + lurbinectedin (IMforte) now approved!

🚀 First-time a drug improves OS after 1L platinum-based chemotherapy in #SCLC and breaks the 12 months OS in maintenance setting. 💊 Lurbinectedin + atezolizumab is now @US_FDA approved. 💪 Another step forward! #LCSM @SclcSMASHERS @PhrmMar https://t.co/deHqxQis4C

👀@FDAOncology approves #lurbinectedin plus #atezolizumab as maintenance therapy for ES- SCLC based on #IMForte study ▶️ important option to improve survival (mOS 13.2 vs 10.6 mos ( HR 0.73) in a fast moving cancer ▶️but not every pt is fit to tolerate chemo early. Is early

Case series of tumor lysis syndrome with the bispecific T-cell engager tarlatamab in patients with small cell lung cancer @ClinicalLung. I have not seen this myself, but for various reasons, tarlatamab in #SCLC could be better with lower disease burden. https://t.co/lpMRTUnTX1

Discuss IMforte w/ @LealTiciana @StephenVLiu & @OncBrothers ?! Anytime! Take 🏠 1) 3 upfront regimens for ES small cell 🫁 cancer. IMforte is 1st w/ PFS OS benefit in maint setting 2) cytopenias are main challenge , use gcsf 3) always shared & informed decision making is 🔑

Join us for a @sclcsmashers Facebook Live on 9/30 w/ @Sonampuri (@MoffittResearch). Dr. Puri joins us to discuss the importance of real-world data for treating #SCLC. Moderated by @drshieldsmd (@IU_Health) and LUNGevity’s @nursesteagall . Tune in at https://t.co/UMN7nNl2O9

Happy to see that earlier evidence on the safety and efficacy of combining lurbinectedin with immunotherapy (2SMALL- atezolizumab; LUPER- pembrolizumab) ultimately helped to improve survival in patients with Small-cell #lungcancer based on the IMforte trial. @SclcSMASHERS #LCSM

Updates to NCCN SCLC guidelines includes the option of maintenance lurbinectedin 3.2mg/m2 (with primary G-CSF) plus atezolizumab after induction (for patients who have not progressed). Based on phase III IMforte study that showed improvement in PFS (HR 0.54) and OS (HR 0.73).